Patents by Inventor Angelica Medina-Selby
Angelica Medina-Selby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7888004Abstract: Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupts the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host cells transformed with polynucleotides and methods of using the polypeptides and polynucleotides are also disclosed.Type: GrantFiled: October 3, 2008Date of Patent: February 15, 2011Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Doris Coit, Angelica Medina-Selby, Mark Selby, Michael Houghton
-
Publication number: 20110014652Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.Type: ApplicationFiled: March 24, 2009Publication date: January 20, 2011Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
-
Publication number: 20110014219Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.Type: ApplicationFiled: March 24, 2009Publication date: January 20, 2011Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
-
Patent number: 7871625Abstract: Modified HCV multiple epitope fusion antigens (MEFAs) are described. The proteins include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited. HCV immunoassays including the modified MEFAs are also described.Type: GrantFiled: August 26, 2005Date of Patent: January 18, 2011Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: David Chien, Doris Coit, Carlos George-Nascimento, Sansan Lin, Angelica Medina-Selby, Laura Tandeske
-
Publication number: 20100291134Abstract: The invention provides truncated HCV NS5 polypeptides and fusion proteins comprising the truncated NS5 polypeptides, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.Type: ApplicationFiled: July 30, 2010Publication date: November 18, 2010Inventors: Michael Houghton, Angelica Medina-Selby, Doris Coit
-
Publication number: 20100291129Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.Type: ApplicationFiled: March 24, 2009Publication date: November 18, 2010Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
-
Patent number: 7807430Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: GrantFiled: March 3, 2008Date of Patent: October 5, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Stephen D Harrison, John A Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y Fang, Doris G Coit, Steve H Nguyen, Angelica Medina-Selby
-
Publication number: 20100092503Abstract: The invention provides HCV fusion polypeptides including truncated or full-length HCV NS5 polypeptides, and a portion of the HCV NS2 polypeptide, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize against HCV.Type: ApplicationFiled: February 27, 2007Publication date: April 15, 2010Inventors: Michael Houghton, Yin-Ling Lin, Angelica Medina-Selby, Doris Coit
-
Publication number: 20090175904Abstract: HBsAg is expressed in a Saccharomyces cerevisiae host, carrying a plasmid having a HBsAg coding sequence, wherein the plasmid includes: (1) an upstream promoter from a glyceraldehyde-3-phosphate dehydrogenase gene, for controlling expression of the HBsAg coding sequence; and (2) an ARG3 transcription terminator downstream of the HBsAg coding sequence. The plasmids may also include: (3) a LEU2 selection marker; (4) a 2? plasmid sequence; and (5) an origin of replication functional in Escherichia coli. HBsAg can be expressed in this host, and can be purified for use in the manufacture of vaccines, and in particular for the manufacture of combination vaccines and in new monovalent HBV vaccines e.g. with non-alum adjuvants.Type: ApplicationFiled: April 14, 2006Publication date: July 9, 2009Inventor: Angelica Medina-Selby
-
Patent number: 7527801Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.Type: GrantFiled: November 22, 2006Date of Patent: May 5, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
-
Publication number: 20090087447Abstract: Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupts the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host cells transformed with polynucleotides and methods of using the polypeptides and polynucleotides are also disclosed.Type: ApplicationFiled: October 3, 2008Publication date: April 2, 2009Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Doris Coit, Angelica Medina-Selby, Mark Selby, Michael Houghton
-
Patent number: 7491808Abstract: Modified HCV non-structural proteins are described. The proteins include modified NS3 domains such that proteolytic activity of the NS3 molecule is inhibited. The modified proteins retain conformational epitopes. HCV immunoassays including the modified NS3 molecules are also described.Type: GrantFiled: August 26, 2005Date of Patent: February 17, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: David Chien, Doris Coit, Celine Hu, Sansan Lin, Angelica Medina-Selby
-
Publication number: 20080299544Abstract: Modified HCV multiple epitope fusion antigens (MEFAs) are described. The proteins include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited. HCV immunoassays including the modified MEFAs are also described.Type: ApplicationFiled: August 26, 2005Publication date: December 4, 2008Inventors: David Y Chien, Doris Coit, Carlos George-Nascimento, Sansan Lin, Angelica Medina-Selby, Laura Tandeske
-
Patent number: 7449566Abstract: Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupts the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host cells transformed with polynucleotides and methods of using the polypeptides and polynucleotides are also disclosed.Type: GrantFiled: August 2, 2005Date of Patent: November 11, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Doris Coit, Angelica Medina-Selby, Mark Selby, Michael Houghton
-
Publication number: 20080182313Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: ApplicationFiled: March 3, 2008Publication date: July 31, 2008Applicant: Novartis Vaccines and Diagonstics, Inc.Inventors: Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
-
Patent number: 7361484Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: GrantFiled: February 8, 2007Date of Patent: April 22, 2008Assignee: Chiron CorporationInventors: Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
-
Patent number: 7319144Abstract: The invention relates to a method of detecting HCV infection in a biological sample, the method comprising providing an immunoassay solid support, comprising an HCV anti-core antibody, an antigen comprising an HCV NS3/4a epitope, and an HCV multiple epitope fusion antigen, that can detect both HCV antigens and antibodies present in a sample. The invention also includes polynucleotides encoding multiple epitope fusion antigens for use in the assay, recombinant vectors and host cells comprising such polynucleotides, and methods of producing the multiple epitope fusion antigens.Type: GrantFiled: August 19, 2003Date of Patent: January 15, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: David Y. Chien, Phillip Arcangel, Laura Tandeske, Carlos George-Nascimento, Doris Coit, Angelica Medina-Selby
-
Publication number: 20070249004Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: ApplicationFiled: February 8, 2007Publication date: October 25, 2007Applicant: Chiron CorporationInventors: Stephen Harrison, John Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Fang, Doris Coit, Steve Nguyen, Angelica Medina-Selby
-
Publication number: 20070207526Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.Type: ApplicationFiled: November 22, 2006Publication date: September 6, 2007Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
-
Patent number: 7241879Abstract: HCV immunoassays comprising an NS3/4a conformational epitope and a multiple epitope fusion antigen are provided, as well as immunoassay solid supports for use with the immunoassays.Type: GrantFiled: July 26, 2004Date of Patent: July 10, 2007Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: David Y. Chien, Phillip Arcangel, Laura Tandeske, Carlos George-Nascimento, Doris Coit, Angelica Medina-Selby